Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

For patients with carotid stenosis ≥50% with a low/intermediate predicted stroke risk, there is no benefit for revascularization added to OMT.

The FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

There is increased risk for cardiotoxicity among Black and Hispanic patients who receive anthracycline chemotherapy for treatment of cancer.

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

A study was conducted to examine the prognostic value of invasive and noninvasive assessment in athletes with complex ventricular arrhythmias.